Partial remission and early stages of pediatric type 1 diabetes display immunoregulatory changes. A pilot study.


Journal

Translational research : the journal of laboratory and clinical medicine
ISSN: 1878-1810
Titre abrégé: Transl Res
Pays: United States
ID NLM: 101280339

Informations de publication

Date de publication:
08 2019
Historique:
received: 11 12 2018
revised: 04 03 2019
accepted: 07 03 2019
pubmed: 7 4 2019
medline: 7 11 2019
entrez: 7 4 2019
Statut: ppublish

Résumé

Type 1 diabetes (T1D) is a chronic metabolic disease of unknown etiology that results from β-cell destruction. The onset of the disease, which arises after a long asymptomatic period of autoimmune attack, may be followed by a relapsing and remitting progression, a phenomenon that is most evident during the partial remission phase (PR). This stage lasts for a few months, shows minor requirements of exogenous insulin and could be explained by a recovery of immunological tolerance. This study aims to identify new biomarkers at early stages of pediatric T1D that reflect immunoregulatory changes. To that end, pediatric patients with T1D (n = 52) and age-related control subjects (n = 30) were recruited. Immune response-related molecules and lymphocyte subsets were determined starting at T1D onset and until the second year of progression. Results showed that circulating TGF-β levels decreased during PR, and that betatrophin concentration was increased in all the considered stages without differing among studied checkpoints. Moreover, an increase of regulatory T, B and NK subsets was found during T1D progression, probably reflecting an attempt to restore self-tolerance. By contrast, a reduction in monocyte levels was observed at the early stages of diabetes. The results reveal significant changes in immunological parameters during the different early stages of T1D in children, which could ultimately serve as potential biomarkers to characterize the progression of T1D.

Identifiants

pubmed: 30953609
pii: S1931-5244(19)30053-2
doi: 10.1016/j.trsl.2019.03.002
pii:
doi:

Substances chimiques

ANGPTL8 protein, human 0
Angiopoietin-Like Protein 8 0
Angiopoietin-like Proteins 0
Biomarkers 0
Peptide Hormones 0
Transforming Growth Factor beta 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

8-25

Informations de copyright

Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.

Auteurs

Adrian Villalba (A)

Immunology Section, Germans Trias i Pujol Research Institute, Badalona, Spain.

Mireia Fonolleda (M)

Immunology Section, Germans Trias i Pujol Research Institute, Badalona, Spain.

Marta Murillo (M)

Pediatrics Section, Germans Trias i Pujol Research Institute and University Hospital, Autonomous University of Barcelona, Badalona, Spain.

Silvia Rodriguez-Fernandez (S)

Immunology Section, Germans Trias i Pujol Research Institute, Badalona, Spain.

Rosa-Maria Ampudia (RM)

Immunology Section, Germans Trias i Pujol Research Institute, Badalona, Spain.

David Perna-Barrull (D)

Immunology Section, Germans Trias i Pujol Research Institute, Badalona, Spain.

Maria Belen Raina (MB)

Pediatrics Section, Germans Trias i Pujol Research Institute and University Hospital, Autonomous University of Barcelona, Badalona, Spain.

Bibiana Quirant-Sanchez (B)

Immunology Section, Germans Trias i Pujol Research Institute, Badalona, Spain.

Raquel Planas (R)

Immunology Section, Germans Trias i Pujol Research Institute, Badalona, Spain.

Aina Teniente-Serra (A)

Immunology Section, Germans Trias i Pujol Research Institute, Badalona, Spain.

Joan Bel (J)

Pediatrics Section, Germans Trias i Pujol Research Institute and University Hospital, Autonomous University of Barcelona, Badalona, Spain.

Marta Vives-Pi (M)

Immunology Section, Germans Trias i Pujol Research Institute, Badalona, Spain; CIBER of Diabetes and Associated Metabolic Disease (CIBERDEM). ISCIII, Barcelona, Spain. Electronic address: mvives@igtp.cat.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH